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A B S T R A C T
The treatment of patients with refractory/relapsed B cell non-Hodgkin lymphoma (NHL) is evolving because
of the availability of novel drugs. Allogeneic stem cell transplantation (alloSCT) can be curative, but its mor-
bidity and mortality remain a matter of concern. We conducted a multicenter prospective phase II trial to
evaluate the benefit of including only 1 dose of rituximab in the conditioning regimen before alloSCT. The
primary endpoint was progression-free survival. The study enrolled 121 patients with relapsed/refractory B
cell lymphomas. The conditioning regimen consisted of thiotepa, cyclophosphamide, fludarabine, and rituximab
(500 mg/m2). Rabbit antithymocyte globulin was administered only in case of unrelated donors. Sixty-seven
(55%) and 54 (45%) patients received grafts from related and unrelated donors, respectively. The crude cu-
mulative incidence (CCI) of nonrelapse mortality (NRM) was 21% at 3 years. The CCIs of chronic graft-verus-
host disease (GVHD) at 3 years were 54% and 31% in recipients of matched sibling and unrelated grafts,
respectively. At a median follow-up of 41 months, the estimated 3-year progression-free and overall survival
were 50% and 61%, respectively. Long-term outcome was also evaluated with the composite endpoint of GVHD-
free and relapse-free survival (GRFS). This is the first work evaluating the GRFS in a prospective trial of lymphoma
patients: the 1-year and 3-year GRFS were 40% and 34%, respectively. AlloSCT can cure a fraction of patients
with rather low NRM and an encouraging PFS and GRFS.
© 2017 American Society for Blood and Marrow Transplantation.
INTRODUCTION
Rituximab-based chemoimmunotherapy has improved
the survival rate of patients with indolent and aggressive
B cell non-Hodgkin lymphoma (NHL) [1,2], but 50% of them
fail to respond or relapse and only a fraction could be cured
by autologous stem cell transplantation (autoSCT). Despite
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an increase of novel drugs and treatments [3], allogeneic
stem cell transplantation (alloSCT) still represents the only
chance of cure for patients relapsing after autoSCT or 2 lines
of chemo-immunotherapy. In previous studies with reduced-
intensity conditioning, we reported a 5-year progression-
free survival (PFS) of 57% and 54% in indolent and aggressive
lymphomas, respectively [4,5].
Severeacutegraft-versus-hostdisease (GVHD)andextensive
chronic GVHD [6,7] are the 2 main complications associated
with transplantation andmay affect bothnonrelapsemortality
(NRM) and quality of life. In recent years, a better understand-
ing of GVHD biology prompted the design of novel GVHD
prophylaxis regimens, including theuseof post-transplantation
cyclophosphamideorproteasome inhibitors, but the gold stan-
dard is still based on calcineurin inhibitors and methotrexate
or mycophenolate mofetil [8-12].
B cells have a role in the pathogenesis of both acute GVHD
(for their role as antigen-presenting cells) and chronic GVHD
(for the production of autoantibodies from autoreactive B cells)
[13]. Rituximab has been introduced during the condition-
ing regimen in very few trials; however, the results on disease
control and prevention of acute or chronic GVHD are still
unclear [14-16]. The major experience was derived from the
pivotal studies of Khouri [14], which showed rather good
disease control with the unexpected finding of a limited in-
cidence of acute and chronic extensive GVHD.
In the present multicenter, prospective, phase II study,
we investigated the effect of a single dose of rituximab
(500 mg/m2) in combination with a reduced-intensity con-
ditioning (RIC) regimen on the PFS of refractory/relapsed B
cell lymphomas. In addition, overall survival, incidence of
acute and chronic GVHD, and GVHD-free, relapse-free sur-
vival (GRFS) were evaluated.
MATERIALS AND METHODS
Patient Characteristics
Between December 2007 and December 2015, 121 patients were en-
rolled in a prospective study (EUDRACT 2007-003657-87) involving 22 Italian
hematology divisions. Inclusion criteria were as follows: (1) patients were
diagnosed with CD20+ B cell NHL (ie, chronic lymphocytic leukemia [CLL],
small lymphocytic lymphoma [SLL], follicular lymphoma [FL], mantle cell
lymphoma [MCL], de novo or transformed diffuse large B cell lymphoma
[DLBCL]) relapsing or refractory after at least 2 lines of treatment or after
failure of autoSCT; (2) MCL and DLBCL were required to have chemosensi-
tive disease; and (3) chemorefractory disease was allowed only for indolent
lymphomas. Exclusion criteria were central nervous system localization,
positive serologic markers for human immunodeficiency virus, active
hepatitis B virus or hepatitis C virus infection, ejection fraction < 45%
(or myocardial stroke in the last year), diffusion capacity of the lung for
carbon monoxide < 50%, no adequate renal and hepatic functions (clear-
ance of creatinine < 50mL/minute, serum bilirubin levels >2 the upper normal
limit). All the patients received rituximab chemo as salvage before trans-
plantation. The study was approved by the institutional review board of all
participating centers.
Donors and Treatment Plan
Donors age ranged between 18 and 65 years old in the case of identi-
cal sibling donors and between 18 and 60 years old in the case of unrelated
donors, The availability of HLA-identical or 1-antigen-mismatched (class I)
sibling donors or unrelated donors mismatched by 1 antigen or allele at
HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1 loci were identified by
high- or intermediate-resolution typing.
Patients were registered at time of relapse. At registration, patients
were treated with salvage rituximab chemotherapy. The choice of the salvage
regimen was left to center preference. All the patients included in this pro-
spective trial received the following drugs intravenously: rituximab
(500 mg/m2, day −6), thiotepa (6 mg/kg every 12 hours for 2 doses, day −5),
cyclophosphamide (30 mg/kg, days −4 and −3), and fludarabine (30 mg/m2,
days −4 and −3, administered 4 hours after cyclophosphamide administra-
tion). The choice to administer only 1 dose of rituximab was related to the
fact that rituximab was already administered with the previous salvage
chemo-immunotherapy. In the case of matched related sibling donors, the
GVHD prophylaxis consisted of intravenous or oral cyclosporine A, ad-
justed tomaintain blood levels at 200 ng/mL to 300 ng/mL, and a short course
of intravenous methotrexate (10 mg/m2 on day +1, and 8 mg/m2 on days +3
and +6). Patients with a class I antigen mismatch (sibling donors) or with
unrelated donors received intravenous rabbit antithymocyte globulin
(ATG, Thymoglobuline, Genzyme-Sanofi; .5mg/kg on day −4, 3mg/kg on day
−3, 3.5 mg/kg on day −2). On day 0, patients received stem cells > 3 × 108/kg
total nucleated stem cells in case of bone marrow and ≥4 × 106/kg CD34+
in case of peripheral blood stem cells. In absence of active acute GVHD, GVHD
prophylaxis was administered until day 100 for siblings and day 150 for un-
related donors (details on immunosuppression tapering are given in
Supplemental Material). Recommendations for supportive care were pre-
viously described [5].
Study Endpoints
The primary endpoint of the study was PFS. The secondary endpoints
were NRM, acute GVHD incidence within 100 days of alloSCT, chronic GVHD
incidence after 100 days, and overall survival (OS). The study sample size
was calculated to estimate the 1-year PFS and corresponding 90% 1-sided
confidence interval. In a retrospective series of 115 patients with relapsed/
refractory B cell NHL, 1-year PFS was 70%, with relapse of 20% [5]. Assuming
no treatment effect on NRM and a 35% relative improvement of relapse rate
(from 20% to 13%), at a significance level of 10% (1-sided test) a sample size
of 190 assessable patients ensured a 80% probability of detecting a 70% to
77% increase in 1-year PFS. However, because of the expansion of trials in-
corporating novel agents and an increase of haploidentical donor use, the
accrual rate decreased in the last 2 years and the data safety and monitor-
ing committee suggested stopping enrollment; also, a change in PFS was
considered very unlikely. Therefore, the primary endpoint of improving PFS
was not met. However, we also analyzed our study using the novel com-
posite endpoint of GRFS, which gives more information regarding GVHD.
Response Criteria and Statistical Analysis
The response to therapy was evaluated at 1, 3, and 6months after alloSCT
and every 6 months thereafter and was measured using the International
Workshop NHL criteria, as previously described [17]. Acute GVHDwas evalu-
ated using the criteria previously described by Glucksberg et al. [18]. Chronic
GVHD was diagnosed according to the Seattle criteria [19]. Chronic GVHD
was not evaluated by the National Institute of Health criteria because the
study was designed before 2007. The incidence of NRM, relapse, and acute
and chronic GVHD were estimated in a competing risks setting using cu-
mulative incidence estimates and the curves were compared by means of
the Gray test. In the estimation of GVHD, death without GVHD was evalu-
ated as a competing event. NRM and relapse were competing events for each
other [20]. We also tested the composite endpoint GRFS [21], introduced
in the 2015, which reflects survival free of major complications. GRFS events
were defined as grade 3 or 4 acute GVHD or chronic GVHD requiring sys-
temic immunosuppressive treatment at any time, disease relapse, or death
from any cause during the first 12 and 36 months after alloSCT. The OS, PFS,
and GRFS curves were estimated using the Kaplan-Meier method and the
curves were compared by means of the log-rank test. Univariable and mul-
tivariable analyses were performed using Fine and Gray (GVHD, NRM, relapse)
or Cox regression models (OS, PFS, GRFS) to assess association between base-
line characteristics and the endpoints [22] The statistical association level
was evaluated by means of Wald tests. In all the analyses, age at transplan-
tation was evaluated as continuous variable using 3-knot restricted cubic
spline. In the multivariable analysis for the evaluation of factors influenc-
ing acute and chronic GVHD, variables (age, donor type, and donor gender)
were chosen based on clinical considerations, and we did not apply any sta-
tistical procedures for variable selection. Statistical analyses were performed
with SAS (SAS Institute, Cary, NC) and R software (R Development Core Team
(2012). R: A language and environment for statistical computing. R Foun-
dation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL
http://www.R-project.org/. Last access: July 7th 2016).
RESULTS
Patient Characteristics
One hundred twenty-one patients with relapsed/refractory
lymphoma were enrolled in this multicenter, prospective,
phase II trial (refer to Table 1 for baseline characteristics of
patients). Themedian agewas 52 years (range, 24 to 65 years).
Diagnoses were de novo or transformed DLBCL (n = 35, of
which 2 transformed and 33 de novo), MCL (n = 22), and in-
dolent lymphomas (FL, n = 35; CLL/SLL, n = 29). Sixty-seven
out of 121 (55%) underwent transplantation from a related
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sibling (1 mismatched siblings in only 2 cases) and 54 (45%)
received a graft from an unrelated donor (34 matched, 20
mismatched). Twelve patients had mismatches in class I and
the rest had mismatches in class II. Interestingly, only 3 pa-
tients out of 20 (15%) had antigenic mismatches at locus C.
It is important to note that most of the patients had a che-
mosensitive disease (complete remission [CR], n = 48 [39%];
partial remission, n = 61 [51%]) at transplantation.
Cumulative Incidence of NRM and GVHD
At a median follow-up of 41 months (range, 6 to 95
months), 24 patients died (20%) of treatment-related causes:
acute GVHD (n = 5), chronic GVHD (n = 3), infections (n = 11),
thrombotic microangiopathy (n = 1), cardiovascular compli-
cations (n = 3), and liver failure (n = 1). The estimated 1-year
and 3-year crude cumulative incidence rates (CCI) of NRM
were 16% (95% confidence interval [CI], 11% to 25%) and 21%
(95% CI, 14% to 30%), respectively (Figure 1). NRM, by uni-
variate analysis (Table S1), was not affected by donor type
(CCI at 1 year: 14% versus 19% in matched sibling donors and
unrelated donors, respectively [P = .325]) nor by lymphoma
subtype (CCI at 1 year: 16% versus 17% in indolent and
aggressive lymphomas, respectively [P = .80]). When we per-
formed a multivariate analysis, NRM did not appear to be
influenced either by age at transplantation, histotype, or by
a previously failed autoSCT (Table 2). However, a higher hazard
ratio (HR) was estimated for sex mismatch (female donor to
male recipient versus other combinations: HR, 2.5; 95% CI,
.91 to 6.97; P = .076), although results remained nonsignifi-
cant. Twenty-six patients (22%) were diagnosed with acute
GVHD grade II to IV (n = 16 grade II, n = 9 grade III, and n = 1
grade IV) with an estimated CCI of 22% (95% CI, 15% to 30%).
Two patients experienced late-onset acute GVHD beyond day
100 and were excluded from the CCI evaluation. The CCI of
Table 1
Patient Characteristics (n = 121)
Characteristic Value
Age at AlloSCT, median (range), yr 52 (23-65)
Gender
Male 80 (66)
Female 41 (34)
Karnofsky performance status
≤80 18 (15)
>80 103 (85)
Diagnosis*
FL 35 (28)
CLL/S CLL 29 (24)
DLBCL 35 (28)
MCL 22 (18)
Bone marrow involvement
Yes 30 (25)
No 79 (65)
Missing 12 (10)
Extranodal involvement
Yes 26 (21)
No 78 (64)
Missing 17 (14)
Prior autoSCT
Yes 74 (61)
No 47 (39)
Disease status at transplantation
CR 48 (40)
PR 64 (53)
PD/SD 9 (7)
Donor type
Matched/mismatched related† 67 (55)
Matched unrelated 34 (28)
Mismatched unrelated 20 (17)
Sex mismatched
Female donor-male recipient 22 (18)
Other combinations 90 (74)
Missing 9 (7)
Stem cell source
PBSC 101 (83)
BM 20 (17)
Year of allogeneic transplantation
2007-2011 65 (54)
2012-2015 56 (46)
Data presented are n (%) unless otherwise indicated.
PR indicates partial remission; PD, progressive disease; SD, stable disease;
PBSC, peripheral blood stem cells; BM, bone marrow.
* Diagnosis were well balanced: 34 and 30 indolent lymphomas pa-
tients received transplants from matched /mismatched related sibling,
respectively; 33 and 20 patients with aggressive lymphomas received trans-
plants from matched/mismatched unrelated donors.
† Includes 2 cases mismatched related.
Figure 1. (A) Crude cumulative Incidence (CCI) of NRM. At 3 years, the CCI
of NRM was 21% (95% CI, 14% to 29%); (B) CCI of acute GVHD grade II to IV
at 100 days: 21% (95% CI,15% to 30%); (C) CCI of limited and extensive chronic
GVHD: 27% (95% CI, 195 to 38%) and 17% (95% CI, 11% to 27%), respectively.
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acute GVHD was not significantly different in patients re-
ceiving grafts from sibling and from unrelated donors (21%
versus 22%, respectively).
Ninety-four patients (77%) were evaluable for chronic
GVHD, whereas the others 27 were not included because
of early death (n = 18), short follow-up (n = 7), or an over-
lapping syndrome of acute and chronic GVHD (n = 2). The CCI
of chronic GVHD at 3 years was 44% (95% CI, 34% to 56%) with
a median time to onset of 353 days. Curves related to acute
and chronic GVHD are reported on Figure 1. According to the
modified Seattle criteria, the CCI of extensive GVHD was 17%
(95% CI, 11% to 27%) whereas the CCI of limited formwas 27%
(95% CI, 19% to 39%) (Figure S1). In the univariable Fine and
Gray model, the only factor that was protective against the
occurrence of GVHD was transplantation from unrelated
donors when rituximab and ATG were combined together
(HR, .50; 95% CI, .25 to .99; P = .05). The CCIs of chronic GVHD
at 3 years were 54% (95% CI, 42 to 1%) and 31% (95% CI, 19%
to 49%) for patients allografted from matched sibling and
unrelated donors, respectively (P = .04). The analysis of as-
sociation between the occurrence of acute and chronic GVHD
with different endpoints was performed by including each
GVHD type as time-dependent covariate in univariable Cox
model. The occurrence of acute GVHD significantly in-
creased the risk of NRM (HR, 3.33; 95% CI, 1.44 to 7.71;
P = .005). NRM and acute and chronic GVHD were not affect-
ed by donor type (matched sibling, matched andmismatched
unrelated) (curves reported in Supplemental Material). There
were no cases of Epstein-Barr virus (EBV) lymphoproliferative
disorders.
Relapse
Thirty patients relapsed (25%) and 18 of them died of
disease (n = 11 aggressive DLBCL, n = 7 CLL). The CCIs of
relapse were 19% (95% CI, 13% to 28%) at 12 months and 27%
(95% CI, 19% to 37%) at 3 years. In particular, the CCI of relapse
at 3 years was 17% and 34% in indolent and aggressive
histotypes, respectively (P = .011). By multivariate analysis,
a positive bone marrow infiltration at the time of transplan-
tation (adjusted HR, 3.18; 95% CI, 1.16 to 8.66; P = .024) and
aggressive histotypes (adjusted HR; 3.03; 95% CI, 1.14 to 8.08;
P = .026) were associated with higher relapse risk.
PFS, OS, and GRFS
Seventy-nine (65%) patients are currently alive, with a
median follow-up for surviving patients of 41 months (range,
6 to 95 months). The estimated 3-year PFS and OS were 50%
and 61%, respectively. (Figure 2). At 3 years, the PFS and OS
were as follows in the different subtypes: 70% (95% CI, 52%
to 82%) and 76% (95% CI, 59% to 86%) in FL, 60% (95% CI, 40%
to 75%) and 66% (95% CI, 45% to 80%) in CLL/SLL, 40% (95%
CI, 23% to 57%) and 52% (95% CI, 32% to 68%) in DLBCL, and
Table 2
Multivariable Analysis on NRM and Relapse
Factor NRM Relapse
HR (95% CI) P Value HR (95% CI) P Value
Age at AlloSCT, yr
46 versus 57* 1.45 (.73-2.86) .55 — —
Histotype subgroup
Aggressive versus indolent 1.07 (.44-2.60) .891 3.03 (1.14-8.08) .026
Bone marrow involvement
Yes versus no — — 3.18 (1.16-8.66) .024
Extranodal involvement
Yes versus no — — .95 (.28-3.18) .930
Prior AutoSCT
Yes versus no 1.82 (.66-5.06) .250 1.11 (.35-3.47) .860
Donor type
Unrelated versus related 1.75 (.75-4.08) .197 .80 (.31-2.05) .640
Sex mismatched
Female donor-male recipient versus Other combinations 2.52 (.91-6.97) .076 .12 (.01-1.15) .067
Bold typeface indicates statistical significance.
* Age was evaluated as continuous variable. The 2 values are, respectively, the third and first quartiles of the variable distribution.
Figure 2. Kaplan-Meier estimates of progression-free survival and overall
survival. (A) PFS at 5 years was 49% (95% CI, 40% to 61%). (B) OS at 5 years
was 61% (95% CI, 51% to 71%).
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52% (95% CI, 28% to 71%) and 66% (95% CI, 39% to 83%) in
MCL. In the 2 cohorts (indolent and aggressive), we evalu-
ated the impact of different prognostic factors on PFS and OS:
(1) time from diagnosis to alloSCT, (2) previous autoSCT; and
(3) disease status at time of allograft (CR versus others).
Neither of these factors influenced significantly PFS or OS. In
the indolent subtype, patients in CR had a better PFS al-
though the difference was not statistically significant (3 year
PFS: 73%; 95% CI, 50% to 86% versus 52%; 95% CI, 35% to 67%;
P = .099) but the status of disease did not influence OS. In the
aggressive subtype, there was again a better survival for pa-
tients who were allografted while in CR (3 year PFS: 75%; 95%
CI, 49% to 88% versus 43%; 95% CI, 23% to 61%; P = .091) but
the difference was not statistically significant.
Univariate analysis for all the patients is shown in the Sup-
plementary Methods (Table S2). The multivariate analysis for
the PFS and OS showed that patients affected by an aggres-
sive histotype had a worst outcome (PFS: HR, 3.30; P = .003;
OS: HR, 3.73;P = .007). Bone marrow infiltration at time of
transplantation increased the risk of disease relapse and death
(PFS: HR, 4.78; P < .001; OS: HR, 6.00; P < .001). The occur-
rence of acute GVHDwas associatedwith shorter OS (HR, 2.31;
95% CI, 1.20 to 4.44; P = .012).
For the entire cohort of patients, the 1-year and 3-year
GRFS were 40% (95% CI, 32% to 50%) and 34% (95% CI, 26%
to 44%), respectively (Figure 3A). The GRFS at 3 years was sig-
nificantly better in patients with indolent as opposed to
aggressive lymphomas (43%; 95% CI, 32% to 58% versus 22%;
95% CI, 13% to 38%; HR 1.69; P = .02), mainly because of a lower
relapse risk (Figure 4). These figures remained unchanged
at 5 years (data not shown). The 3-year GRFS was 41% and
30% in patients in CR and partial remission at the time of
transplantation, respectively (P = .075). There was a trend for
a better outcome in CR patients. The 3-year GRFS was 27%
and 41% in patients allografted from matched sibling and
unrelated donors, respectively (P = .096) (Figure 3B). Distri-
bution of individual components of GRFS is given in
SupplementaryMethods (Figure S5 and S6). Main clinical char-
acteristics were not different between patients receiving
sibling or matched unrelated donor transplants; therefore,
the difference in GRFS was caused by lower chronic GVHD
requiring systemic therapy in patients allografted from un-
related donors. In multivariable model, the same factors
affecting PFS and OS significantly influenced GRFS (histotype:
HR, 2.02; P = .026; bonemarrow infiltration: HR: 2.70; P < .004)
(Table 3).
DISCUSSION
In this large, multicenter, prospective, phase II trial, we
explored the effect of the inclusion of rituximab in a RIC
regimen for B cell lymphomas. Our findings showed that:
(1) 3-yearNRMwas low (21%); (2) PFSwas not improved com-
paredwith our previous datawithout rituximab; (3) extensive
chronic GVHD was low despite the high proportion of pa-
tients (45%) allografted from unrelated donors; (4) because
Figure 3. Adjusted Kaplan-Meier estimates of GVHD-free and relapse-free
survival (GRFS) at 3 years after allogeneic stem cell transplantation. (A) GRFS
for all the patients: 34% (95% CI, 26% to 44%); (B) GRFS according to donor
type: 27% and 41% in patients allografted from matched sibling donors and
unrelated donors, respectively (P = .09).
Figure 4. Adjusted Kaplan-Meier estimates of graft-versus-host disease-
free and relapse-free survival (GRFS) at 3 years after allogeneic stem cell
transplantation. (A) GRFS upon histotype: 43% indolent (95% CI, 32% to 58%)
versus 22% aggressive lymphomas (95% CI, 13% to 38%), (P = .02); (B) GRFS
upon pretransplantation disease status: 41% (95% CI, 28% to 59%) and 30%
(95% CI, 20% to 44%) for patients in complete and partial remission, respec-
tively (P = .185).
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of rituximab inclusion, there were no EBV-related post-
transplantation lymphoproliferative disorders (PTLD); and
(5) a lower incidence of chronic GVHD did not translate in a
higher relapse rate.
In a previous trial, we showed that alloSCT is an effec-
tive option for relapsed/refractory lymphomas. We conducted
a clinical trial in 170 patients with different B and T lym-
phoma subtypes allografted only frommatched sibling donors
with a RIC regimen and we obtained an encouraging NRM
(14%) with PFS of 56%, but the trial was complicated by a CCI
of 14% for severe acute GVHD (overall 35%) and 25% of chronic
extensive form (overall 49%) [5]. Most of reports show that
approximately 50% of patients can be free of progression after
alloSCT. To improve PFS, we designed the present trial in-
cluding rituximab in the conditioning regimen; however,
we show that while there was no benefit in terms of disease
control, there was an advantage in terms of chronic GVHD
occurrence. In general, when chronic GVHD decreases, there
is an increased relapse rate; interestingly, this was not the
case with the addition of rituximab.
Despite several studies conducted over the last decade that
showed a significant decrease in NRM after alloSCT with RIC
regimens [5], further progress is needed to improve GVHD
prophylaxis, as GVHD is a major determinant of morbidity
and mortality. To improve the above reported results (using
also unrelated donors), we performed the present trial, which
included a single dose of rituximab (500 mg/m2) adminis-
tered during the conditioning. The rationale for the single
pretransplantation rituximab administration relies on the
assumption that circulating CD20+ B cells of the recipient
had already been depleted by rituximab-supplemented
salvage chemo-immunotherapy, whereas pretransplantation
rituximab will probably work largely by depleting the donor’s
alloreactive B cells (and thus also preventing EBV reactiva-
tion) in the first 3 months after transplantation. In the current
study, the incidence of acute GVHD (21% and 22% in trans-
plantations from related and unrelated donors, respectively)
was lower than in our previous studywithout rituximab (35%),
which included only patients allografted from HLA-matched
siblings andwho received the same conditioning regimen and
GVHD prophylaxis [5]. The 3-year CCI of chronic GVHD was
31% versus 54% in patients allografted from unrelated and
related donors, respectively. This finding is clinically rele-
vant and could be related to the high-dose ATG used or to a
potential synergistic effect of rituximab and ATG. This result
substantially contributes in generating a 41% GRFS in pa-
tients allografted from unrelated donors. The dose of ATG in
our trial was not associated with unacceptable risk of infec-
tion and derived from a previous Italian trial [23] that
evaluated 2 different GVHD prophylaxis strategies (ATG at
7.5 mg/kg versus alemtuzumab) in patients who received a
graft from unrelated donors (8/8 or 7/8 [a single allele mis-
matchwas allowed]). For all patients, the cumulative incidence
of acute and chronic GVHD were 44% and 25%, respectively.
The impact of rituximab on B cell depletion has been
previously evaluated in different trials with conflicting
results. First, the dose, timing, and duration of antibody ad-
ministration was variable. Second, these studies are not easily
comparable to each other not only for the type of patients
enrolled, but also for differences in the conditioning regi-
mens as well as in the type and dose of the drugs used for
GVHD prophylaxis (eg, ATG) [14,15]. Khouri et al. [14] were
the first to explore the administration of high-dose rituximab
(before and after transplantation) and reported results with
a mature follow-up. They showed an impressive low inci-
dence (10%) of grade III and IV acute GVHD and of extensive
chronic GVHD (36%), which appeared to be not only related
to patient selection (mainly matched sibling donors) but also
to antibody administration. In that study, rituximab-naive pa-
tients were included. In a more recent paper [24], the same
authors explored a new reduced-conditioning regimen
(bendamustine, fludarabine, and rituximab), but they also
introduced also a low-dose ATG for recipients of unrelated
grafts. The 2-year cumulative incidence of chronic GVHDwas
26% in patients who received a graft from unrelated donors,
which is comparable to our results. Recently, Laport et al. [25]
performed a prospective trial using the fludarabine, cyclo-
phosphamide and rituximab regimen in a population of
65 patients who received grafts from matched sibling and
unrelated donors. The authors did not use ATG and the cu-
mulative incidence of chronic GVHD for unrelated recipients
was 66%. Despite that, the study was interesting because
they found associations between higher rituximab serum
concentration with better outcome and lower serum
concentration with severe acute GVHD. Cutler et al. [15]
explored different rituximab infusions after day 100, dem-
onstrating a 30% incidence of chronic GVHD requiring systemic
corticosteroids (lower than 48% observed in the historical
control) in patients who received transplants from related and
unrelated donors.
Table 3
Multivariable Analysis on PFS, OS, GRFS
Factor PFS OS GRFS
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Age at AlloSCT
46 versus 57* 1.63 (.93-2.85) .234 1.70 (.91-3.18) .22 1.62 (1.02-2.55) .113
Histotype subgroup
Aggressive versus Indolent 3.30 (1.49-7.30) .003 3.73 (1.42-9.78) .007 2.02 (1.09-3.77) .026
Prior autoSCT
Yes versus No 1.34 (.60-3.02) .476 1.20 (.48-3.00) .696 1.55 (.78-3.05) .208
Bone marrow involvement
Yes versus no 4.79 (2.12-10.82) <.001 6.00 (2.10-14.15) <.001 2.70 (1.37-5.32) .004
Extranodal involvement
Yes versus no .87 (.40-1.90) .728 1.07 (.45-2.53) .884 1.54 (.82-2.89) .177
Donor type
Unrelated versus related 1.28 (.59-2.76) .529 1.35 (.56-3.3.30) .506 .79 (.41-1.51) .472
Sex mismatched
Female donor-male recipient versus other combinations 1.21 (.48-3.04) .690 1.50 (.53-4.26) .449 1.41 (.68-2.91) .352
Bold typeface indicates statistical significance.
* Age was evaluated as continuous variable. The 2 values are, respectively, the third and first quartiles of the variable distribution.
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In contrast to the above studies, Glass et al. [16] evalu-
ated the effect of post-transplantation rituximab in a
randomized trial and did not observe any significant effect
on either acute or chronic GVHD. However, the major limi-
tation of this prospective trial was the use of ATG in aminority
of patients who received grafts from unrelated donors and
the discontinuation of rituximab in a substantial number of
patients (61%) allocated to the rituximab group.
Recent randomized trials, performed mainly in myeloid
malignancies, strongly supported the use of ATG as GVHD
prophylaxis in patients receiving alloSCT not only from un-
related donors [26] but also from HLA-identical siblings [27].
The benefit was mainly related to a reduction of the severe
forms of chronic GVHD.
EBV reactivation is common (33%) after allogeneic
transplantation from unrelated donors when the GVHD
prophylaxis includes ATG, as recently reported also in the
paper of Walker et al. [26]. High levels of EBV DNAemia
increase the risk of PTLD. The use of prophylactic rituximab
(200 mg on day +5) has been explored in a retrospective
study [28] in recipients of transplants from alternative
donor (the GVHD prophylaxis included rabbit ATG at dose
of 6 mg/kg to 10 mg/kg) and was associated with a lower
rate of EBV DNAemia and the absence of cases of PTLD, as
compared with the control group. In our study, the admin-
istration of rituximab efficiently prevented EBV reactivation
and PTLD.
Our trial expands the knowledge about the role of trans-
plantation in relapsed/refractory aggressive lymphomas. In
fact, we demonstrated that at 3 years, 54% of patients failing
an autoSCT and 43% of patients not in CR are alive. These data
compare favorably with the results reported by Glass et al.
[16] in patients with refractory disease at time of alloSCT
(estimated 3-year OS of 38%) and with those described by
T. Fenske et al. [29] in retrospective study enrolling patients
progressing after autoSCT (estimated 3-year OS of 37%).
In recent years, a number of novel agents for lympho-
mas became available. Major advances occurred in relapsed/
refractory CLL, MCL, and FL using the Bruton tyrosine kinase
inhibitors (ibrutinib); the inhibitor of BCL-2, venetoclax;
and phosphatidylinositol-3-kinase delta inhibitor, idelalisib
[30-33]. All of these studies have intrinsic limitations mainly
because of the very short follow-up. Further, long-term ef-
ficacy and safety data are lacking. The question of which
strategy (RIC alloSCT or new drugs) is better for the treat-
ment of transplantation-eligible patients is now open and
appropriately designed prospective clinical trials will be re-
quired to challenge the 34% of patients who are alive and free
of any complication after alloSCT.
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